NCT06996886View on ClinicalTrials.gov

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

July 25, 2025

Conditions

Healthy Participants

Interventions

DRUG

AZD5004

Participants will be receiving three different formulations (F1, F3, and F4) as single dose of AZD5004 orally in fasted and fed state.

Trial Locations (1)

21225

Research Site, Baltimore

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY